Articles
Page 1 of 9
-
Citation: Cancer Communications 2019 39:82
-
Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1–Survivin axis
High-grade glioma (HGG) is a fatal human cancer. Bortezomib, a proteasome inhibitor, has been approved for the treatment of multiple myeloma but its use in glioma awaits further investigation. This study aimed...
Citation: Cancer Communications 2019 39:81 -
A nomogram for individualized estimation of survival among adult patients with adrenocortical carcinoma after surgery: a retrospective analysis and multicenter validation study
Clinical outcome of adrenocortical carcinoma (ACC) varies because of its heterogeneous nature and reliable prognostic prediction model for adult ACC patients is limited. The objective of this study was to deve...
Citation: Cancer Communications 2019 39:80 -
The immune landscape of esophageal cancer
Esophageal cancer (EC) seriously threatens human health, and a promising new avenue for EC treatment involves cancer immunotherapy. To improve the efficacy of EC immunotherapy and to develop novel strategies f...
Citation: Cancer Communications 2019 39:79 -
Long-lasting responses after discontinuation of nivolumab treatment for reasons other than tumor progression in patients with previously treated, advanced non-small cell lung cancer
Citation: Cancer Communications 2019 39:78 -
Post-translational modification of Parkin and its research progress in cancer
Clinical practice has shown that Parkin is the major causative gene found in an autosomal recessive juvenile parkinsonism (AR-JP) via Parkin mutations and that the Parkin protein is the core expression product of...
Citation: Cancer Communications 2019 39:77 -
Interactions between cancer cells and bone microenvironment promote bone metastasis in prostate cancer
Bone metastasis is the leading cause of death in prostate cancer patients, for which there is currently no effective treatment. Since the bone microenvironment plays an important role in this process, attentio...
Citation: Cancer Communications 2019 39:76 -
Minimally invasive surgery alone compared with intensity-modulated radiotherapy for primary stage I nasopharyngeal carcinoma
The National Comprehensive Cancer Network guidelines recommend intensity-modulated radiotherapy (IMRT) as the primary curative treatment for newly diagnosed nasopharyngeal carcinoma (NPC), but the radiation-re...
Citation: Cancer Communications 2019 39:75 -
Tumor mutational burden as a new biomarker for PD-1 antibody treatment in gastric cancer
Citation: Cancer Communications 2019 39:74 -
Neoadjuvant stereotactic radiosurgery for intracerebral metastases of solid tumors (NepoMUC): a phase I dose escalation trial
More than 25% of patients with solid cancers develop intracerebral metastases. Aside of surgery, radiation therapy (RT) is a mainstay in the treatment of intracerebral metastases. Postoperative fractionated st...
Citation: Cancer Communications 2019 39:73 -
Moving beyond hydroxychloroquine: the novel lysosomal autophagy inhibitor ROC-325 shows significant potential in preclinical studies
Citation: Cancer Communications 2019 39:72 -
Nuclear glycogenolysis modulates histone acetylation: a novel mechanism of epigenetic regulation in cancer
Citation: Cancer Communications 2019 39:71 -
CD137 expression in cancer cells: regulation and significance
Citation: Cancer Communications 2019 39:70 -
The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
Gefitinib, as the first epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC), has been proved to significantly improv...
Citation: Cancer Communications 2019 39:69 -
Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification
Interphase fluorescence in situ hybridization (FISH) of bone marrow cells has been confirmed to be a direct and valid method to assess the v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homo...
Citation: Cancer Communications 2019 39:68 -
A case of EGFR mutation-positive lung adenocarcinoma in which the T790M allele fraction was increased by repeated EGFR-TKI treatment
Citation: Cancer Communications 2019 39:67 -
Laparoscopic versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a propensity score matching analysis
A growing body of evidence supports the use of laparoscopic pancreaticoduodenectomy (LPD) as an efficient and feasible surgical technique. However, few studies have investigated its applicability in pancreatic...
Citation: Cancer Communications 2019 39:66 -
S-1 plus docetaxel: a safe and effective chemotherapy regimen for stage III gastric cancer
Citation: Cancer Communications 2019 39:65 -
Optimal sequencing of chemotherapy with chemoradiotherapy based on TNM stage classification and EBV DNA in locoregionally advanced nasopharyngeal carcinoma
Citation: Cancer Communications 2019 39:64 -
Targeting mitochondria as an anticancer strategy
Citation: Cancer Communications 2019 39:63 -
Incidence trends and survival prediction of hepatoblastoma in children: a population-based study
Hepatoblastoma is a rare disease that nevertheless accounts for the majority of liver malignancies in children. Due to limited epidemiological data, therapy for hepatoblastoma tends to be individualized. This ...
Citation: Cancer Communications 2019 39:62 -
New frontiers in proton therapy: applications in cancers
Proton therapy offers dominant advantages over photon therapy due to the unique depth-dose characteristics of proton, which can cause a dramatic reduction in normal tissue doses both distal and proximal to the...
Citation: Cancer Communications 2019 39:61 -
Prognosis of lymphotropic invasive micropapillary breast carcinoma analyzed by using data from the National Cancer Database
Invasive micropapillary carcinoma (IMPC) is an uncommon subtype of breast cancer. Previous studies of this subtype demonstrated a higher propensity for lymph node metastases as compared with invasive ductal ca...
Citation: Cancer Communications 2019 39:60 -
Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience
A fixed 8-cycle oxaliplatin and capecitabine (XELOX) regimen has been the standard adjuvant therapy for patients with stage III colon cancer. However, completing the full-cycle of oxaliplatin is often associat...
Citation: Cancer Communications 2019 39:59 -
Phase II study of R–CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study
The response rate and survival improvement for rituximab, a CD20-targeting monoclonal antibody, have been demonstrated in marginal zone lymphoma (MZL) as monotherapy and in combination with chemotherapeutic re...
Citation: Cancer Communications 2019 39:58 -
Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer
Breast cancer is a global problem, and a large number of new cases are diagnosed every year. Capecitabine is effective in patients with metastatic breast cancer (MBC). Hand-foot syndrome (HFS) is a common adve...
Citation: Cancer Communications 2019 39:57 -
Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study
Citation: Cancer Communications 2019 39:56 -
A nomogram predicting the recurrence of hepatocellular carcinoma in patients after laparoscopic hepatectomy
Patients with hepatocellular carcinoma (HCC) undergoing surgical resection still have a high 5-year recurrence rate (~ 60%). With the development of laparoscopic hepatectomy (LH), few studies have compared the...
Citation: Cancer Communications 2019 39:55 -
Associations of PGK1 promoter hypomethylation and PGK1-mediated PDHK1 phosphorylation with cancer stage and prognosis: a TCGA pan-cancer analysis
Cancer cells reprogram metabolism for proliferation. Phosphoglycerate kinase 1 (PGK1), as a glycolytic enzyme and newly identified protein kinase, coordinates glycolysis and mitochondrial metabolism. However, ...
Citation: Cancer Communications 2019 39:54 -
Pathological transition as the arising mechanism for drug resistance in lung cancer
Despite the tremendous efforts for improving therapeutics of lung cancer patients, its prognosis remains disappointing. This can be largely attributed to the lack of comprehensive understanding of drug resista...
Citation: Cancer Communications 2019 39:53 -
A novel prognostic prediction tool for postoperative recurrence in patients with stage II/III colon cancer
Citation: Cancer Communications 2019 39:52 -
Poor outcomes of immunoglobulin D multiple myeloma patients in the era of novel agents: a single-center experience
Citation: Cancer Communications 2019 39:51 -
Correction to: Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal carcinoma: a propensity score matched analysis
In the original publication of this article [1], the first affiliation name in the Author details section should be updated to ‘Department of Radiation Oncology, National Cancer Center/National Clinical Resear...
Citation: Cancer Communications 2019 39:50 -
Retrieved lymph nodes from different anatomic groups in gastric cancer: a proposed optimal number, comparison with other nodal classification strategies and its impact on prognosis
The optimal number of retrieved lymph nodes (LNs) in gastric cancer (GC) is still debatable and previous studies proposing new classification alternatives mostly focused on the number of retrieved LNs without ...
Citation: Cancer Communications 2019 39:49 -
Cancer cell reprogramming: a promising therapy converting malignancy to benignity
In the past decade, remarkable progress has been made in reprogramming terminally differentiated somatic cells and cancer cells into induced pluripotent cells and cancer cells with benign phenotypes. Recent st...
Citation: Cancer Communications 2019 39:48 -
Radiation pneumonitis complicated by Pneumocystis carinii in patients with thoracic neoplasia: a clinical analysis of 7 cases
Citation: Cancer Communications 2019 39:47 -
Effects of two types of exercise training on psychological well-being, sleep, quality of life and physical fitness in patients with high-grade glioma (WHO III and IV): study protocol for a randomized controlled trial
There is existing evidence on whether and to what degree regular exercise training improves the quality of life (QoL) among cancer survivors. However, in regards to patients with high-grade glioma (HGG; WHO gr...
Citation: Cancer Communications 2019 39:46 -
Complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases: results of a propensity score matching analysis from France
Citation: Cancer Communications 2019 39:45 -
Clinical outcomes of angiosarcoma: a single institution experience
Citation: Cancer Communications 2019 39:44 -
Impaired dendritic cell functions in lung cancer: a review of recent advances and future perspectives
Lung cancer is the leading cause of cancer mortality worldwide. Dendritic cells (DCs) are the key factors providing protective immunity against lung tumors and clinical trials have proven that DC function is r...
Citation: Cancer Communications 2019 39:43 -
Comparison of screening strategies for Lynch syndrome in patients with newly diagnosed endometrial cancer: a prospective cohort study in China
The prevalence of Lynch syndrome and screening strategies for this disorder in Chinese patients with endometrial cancer have seldom been investigated. Such data would be essential for the screening, prevention...
Citation: Cancer Communications 2019 39:42 -
Regulation of CD137 expression through K-Ras signaling in pancreatic cancer cells
The interaction between CD137 and its ligand (CD137L) plays a major role in the regulation of immune functions and affects cancer immunotherapy. CD137 is a cell surface protein mainly located on activated T ce...
Citation: Cancer Communications 2019 39:41 -
Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis
Promising efficacy and manageable toxicity of docetaxel-based concurrent chemoradiotherapy (CCRT) were reported in head and neck cancer. In addition, the effect of CCRT in combination with cisplatin and/or 5-f...
Citation: Cancer Communications 2019 39:40 -
Induction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinoma
The standard of care for patients with locoregionally advanced nasopharyngeal carcinoma is concurrent platinum-based chemoradiotherapy. Existing literature have demonstrated that the addition of gemcitabine an...
Citation: Cancer Communications 2019 39:39 -
Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial
The JACOB trial (NCT01774786) was a double-blinded, placebo-controlled, randomized, multicenter, international, phase III trial evaluating the efficacy and safety of adding pertuzumab to trastuzumab and chemot...
Citation: Cancer Communications 2019 39:38 -
Somatic mutations in renal cell carcinomas from Chinese patients revealed by targeted gene panel sequencing and their associations with prognosis and PD-L1 expression
Citation: Cancer Communications 2019 39:37 -
China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy
On May 8, 2018, the China National Medical Products Administration (NMPA) approved anlotinib, an orally administered anti-angiogenesis inhibitor, for the treatment of patients with advanced non-small cell lung...
Citation: Cancer Communications 2019 39:36 -
Microscopic tumor foci in axillary lymph nodes may reveal the recurrence dynamics of breast cancer
Citation: Cancer Communications 2019 39:35 -
Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells
Cancer cell growth is associated with immune surveillance failure. Nowadays, restoring the desired immune response against cancer cells remains a major therapeutic strategy. Due to the recent advances in biolo...
Citation: Cancer Communications 2019 39:34 -
Preferable background filtering for next-generation sequencing analysis in non-small cell lung cancer: pericarcinomatous tissues or peripheral blood lymphocytes?
Citation: Cancer Communications 2019 39:33